Hepatitis E in blood donors: prevalence, risks of posttransfusion infection and screening strategy
https://doi.org/10.35754/0234-5730-2025-70-1-85-96
Abstract
Introduction. Hepatitis E virus (HEV) is transmitted primarily through contaminated water and food, but cases of transfusiontransmitted HEV infection (TT-HEV) have also been described. TT-HEV may pose a serious risk for immunosuppressed patients, such as recipients of hematopoietic stem cell transplants or solid organ transplants. The risk of TT-HEV is associated with HEV viremia in asymptomatic donors. In recent years, several European countries and Japan have introduced universal screening of blood donors for HEV RNA.
Aim: to systematize published data on the prevalence of HEV infection among donors and the levels of risk of TT-HEV in different regions of the world, as well as approaches to screening donors for HEV.
Main findings. An analysis of the research data obtained in limited donor cohorts, as well as real-world data obtained following the implementation of universal donor screening indicates the relevance of testing blood donors for HEV RNA. The results of studies conducted in the Russian Federation indicate the frequency of detection of HEV viremia in donors comparable to that observed in countries where universal screening of donors for HEV RNA has already been implemented. The absence of documented cases of TT-HEV in the Russian Federation may be due not to the absence of the problem as such, but to insuffi cient availability of hepatitis E diagnostics and/or the lack of awareness of clinicians regarding this infection.
Supporting agencies: the study had no sponsorship.
About the Authors
I. A. Potemkin
Central Research Institute of Epidemiology of Rospotrebnadzor; I.I. Mechnikov Vaccine and Serum Research Institute
Russian Federation
Russian Federation
111123, Moscow; 105064, Moscow
K. K. Kyuregyan
Central Research Institute of Epidemiology of Rospotrebnadzor; I.I. Mechnikov Vaccine and Serum Research Institute
Russian Federation
Russian Federation
111123, Moscow; 105064, Moscow
M. I. Mikhailov
Central Research Institute of Epidemiology of Rospotrebnadzor; I.I. Mechnikov Vaccine and Serum Research Institute
Russian Federation
Russian Federation
111123, Moscow; 105064, Moscow
References
1. Bi H., Yang R., Wu C., Xia J. Hepatitis E virus and blood transfusion safety. Epidemiol Infect. 2020; 148: e158. DOI: 10.1017/S0950268820001429.
2. Cruz, S., Campos C., Timóteo M., et al. Hepatitis E Virus in Hematopoietic Stem Cell Transplant Recipients: A Systematic Review. J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin Virol. 2019; 119: 31–6. DOI: 10.1016/j.jcv.2019.08.002.
3. Thakur V., Ratho R.K., Kumar S., et al. Viral Hepatitis E and Chronicity: A Growing Public Health Concern. Front Microbiol. 2020; 11: 577339. DOI: 10.3389/fmicb.2020.577339.
4. Ma Z., de Man R.A., Kamar N., Pan Q. Chronic Hepatitis E: Advancing Research and Patient Care. J Hepatol. 2022; 77: 1109–23. DOI: 10.1016/j.jhep.2022.05.006.
5. Tanaka A., Matsubayashi K., Odajima T., et al. Universal Nucleic Acid Donor Screening Revealed Epidemiological Features of Hepatitis E and Prevented Transfusion-Transmitted Infection in Japan. Transfusion. 2024; 64: 335–47. DOI: 10.1111/trf.17696.
6. Kumar N., Sarin S.K. Hepatitis E-is it a risk to transfusion safety? Asian J Transfus Sci. 2013; 7(1): 1–3.
7. Bihl F., Castelli D., Marincola F., et al. Transfusion-transmitted infections. J Transl Med. 2007; 5: 25.
8. Hartl J., Otto B., Madden R.G., et al. Hepatitis E Seroprevalence in Europe: A Meta-Analysis. Viruses. 2016; 8: 211.
9. Potemkin I.A., Kyuregyan K.K., Karlsen A.A., et al. Hepatitis E Virus Infection in Voluntary Blood Donors in the Russian Federation. Viruses. 2024; 16(4): 526. DOI: 10.3390/v16040526.
10. Potemkin I.A., Kyuregyan K. K., Isaeva O.V., et al. Prevalence of HEV markers among blood donors in reign of Russian Federation. Gematologiya I Transfusiologiya. 2013; 58(4): 26–8 (In Russian).
11. Gaponova T.V., Kapranov N.M., Tikhomirov D.S., et al. Characteristics and trends in the work of the Blood Service of the Russian Federation in 2016– 2020. Gematologiya I Transfusiologiya. 2022; 67(3): 388–97 (In Russian). DOI: 10.35754/0234-5730-2022-67-3-388-397.
12. Boland F., Martinez A., Pomeroy L., O’Flaherty N. Blood Donor Screening for Hepatitis E Virus in the European Union. Transfus. Med. Hemotherapy Off. Organ Dtsch. Ges. Transfusionsmedizin Immunhamatol. 2019; 46: 95–103. DOI: 10.1159/000499121.
13. Hewitt P.E., Ijaz S., Brailsford S.R., et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet. 2014; 384(9956): 1766–73. DOI: 10.1016/S0140-6736(14)61034-5.
14. O’Riordan J., Boland F., Williams P., et al. Hepatitis E virus infection in the Irish blood donor population. Transfusion. 2016; 56: 2868–76. DOI: 10.1111/trf.13757.
15. Thom K., Gilhooly P., McGowan K., et al. Hepatitis E virus (HEV) in Scotland: Evidence of recent increase in viral circulation in humans. Euro Surveill. 2018; 23: 17–00174. DOI: 10.2807/1560-7917.ES.2018.23.12.17-00174.
16. Cleland A., Smith L., Crossan C., et al. Hepatitis E virus in Scottish blood donors. Vox Sang. 2013; 105: 283–9. DOI: 10.1111/vox.12056.
17. Grabarczyk P., Sulkowska E., Gdowska J., et al. Molecular and serological infection marker screening in blood donors indicates high endemicity of hepatitis E virus in Poland. Transfusion. 2018; 58: 1245–53. DOI: 10.1111/trf.14531.
18. Miletić M., Vuk T., Hećimović A., et al. Estimation of the hepatitis E assaydependent seroprevalence among Croatian blood donors. Transfus Clin Biol. 2019; 26(4): 229–33. DOI: 10.1016/j.tracli.2019.06.234.
19. Gorski I., Babić I., Bingulac-Popović J., et al. Prevalence of HEV RNA in Croatian blood donors. Transfus Clin Biol. 2023; 30(2): 244–8. DOI: 10.1016/j.tracli.2023.01.005.
20. Harritshøj L.H., Holm D.K., Saekmose SG., et al. Low transfusion transmission of hepatitis E among 25,637 single-donation, nucleic acid-tested blood donors. Transfusion. 2016; 56(9): 2225–32. DOI: 10.1111/trf.13700.
21. Vercouter A.S., Van Houtte F., Verhoye L., et al. Hepatitis E virus prevalence in Flemish blood donors. J Viral Hepat. 2019; 26: 1218–23. DOI: 10.1111/jvh.13161.
22. Rivero-Juarez A., Jarilla-Fernandez M., Frias M., et al. Hepatitis E virus in Spanish donors and the necessity for screening. J Viral Hepat. 2019; 26(5): 603–8. DOI: 10.1111/jvh.13064.
23. Sauleda S., Ong E., Bes M., et al. Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription-mediated amplification assay in blood donors from Catalonia (Spain). Transfusion. 2015; 55: 972–9. DOI: 10.1111/trf.12929.
24. Fischer C., Hofmann M., Danzer M.et al. Seroprevalence and Incidence of hepatitis E in blood donors in Upper Austria. PLoS ONE. 2015; 10: e0119576. DOI: m10.1371/journal.pone.0119576.
25. Kuznetsova T., Moor D., Khanirzayeva G., Geller J. Evaluation of Prevalence of Hepatitis E Clinical Markers among Donors in Estonia. Viruses. 2023; 15(10): 2118. DOI: 10.3390/v15102118.
26. Cordes A.K., Goudeva L., Lutgehetmann M., et al. Risk of transfusion-transmitted hepatitis E virus infection from pool-tested platelets and plasma. J Hepatol. 2022; 76: 46–52. DOI: 10.1016/j.jhep.2021.08.018.
27. Vollmer T., Diekmann J., Knabbe C., Dreier J. Hepatitis E virus blood donor NAT screening: As much as possible or as much as needed? Transfusion. 2019; 59: 612–22. DOI: 10.1111/trf.15058.
28. Westholter D., Hiller J., Denzer U., et al. HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients. J Hepatol. 2018; 69: 36–42. DOI: 10.1016/j.jhep.2018.02.031.
29. Spada E., Simeoni M., Martina A., et al. Prevalence and risk factors for hepatitis E virus infection in blood donors: a nationwide survey in Italy, 2017 to 2019. Euro Surveill. 2022; 27(22): 2100516. DOI: 10.2807/1560-7917.
30. Spreafico M., Raffaele L., Guarnori I., et al. Prevalence and 9-year incidence of hepatitis E virus infection among North Italian blood donors: Estimated transfusion risk. J Viral Hepat. 2020; 27: 858–61. DOI: 10.1111/jvh.13296.
31. Spada E., Pupella S., Pisani G., et al. A nationwide retrospective study on prevalence of hepatitis E virus infection in Italian blood donors. Blood Transfus. 2018; 16: 413–21. DOI: 10.2450/2018.0033-18.
32. Fearon M.A., O’Brien S.F., Delage G., et al. Hepatitis E in Canadian blood donors. Transfusion. 2017; 57: 1420–25. DOI: 10.1111/trf.14089.
33. Roth N.J., Schafer W., Alexander R., et al. Low hepatitis E virus RNA prevalence in a large-scale survey of United States source plasma donors. Transfusion. 2017; 57: 2958–64. DOI: 10.1111/trf.14285.
34. Stramer S.L., Moritz E.D., Foster G.A., et al. Hepatitis E virus: Seroprevalence and frequency of viral RNA detection among US blood donors. Transfusion. 2016; 56: 481–8. DOI: 10.1111/trf.13355.
35. Xu C., Wang R.Y., Schechterly C.A., et al. An assessment of hepatitis E virus (HEV) in US blood donors and recipients: No detectable HEV RNA in 1939 donors tested and no evidence for HEV transmission to 362 prospectively followed recipients. Transfusion. 2013; 53: 2505–11. DOI: 10.1111/trf.12326.
36. Hoad V.C., Seed C.R., Fryk J.J., et al. Hepatitis E virus RNA in Australian blood donors: Prevalence and risk assessment. Vox Sang. 2017; 112: 614–21. DOI: 10.1111/vox.12559.
37. Shrestha A.C., Flower R.L., Seed C.R., et al. Hepatitis E virus RNA in Australian blood donations. Transfusion. 2016; 56: 3086–93. DOI: 10.1111/trf.13799.
38. Nouhin J., Prak S., Madec Y., et al. Hepatitis E virus antibody prevalence, RNA frequency, and genotype among blood donors in Cambodia (Southeast Asia). Transfusion. 2016; 56: 2597–601. DOI: 10.1111/trf.13731.
39. Guo Q.S., Yan Q., Xiong J.H., et al. Prevalence of hepatitis E virus in Chinese blood donors. J Clin Microbiol. 2010; 48: 317–8. DOI: 10.1128/JCM.01466-09.
40. Tsoi W.C., Zhu X., To A.P., Holmberg J. Hepatitis E virus infection in Hong Kong blood donors. Vox Sang. 2020; 115: 11–7. DOI: 10.1111/vox.12846.
41. Fu P., Lin B., Wu B., et al. Hepatitis E virus prevalence among blood donors in Dali, China. Virol. J. 2021; 18: 141. DOI: 10.1186/s12985-021-01607-y.
42. Minagi T., Okamoto H., Ikegawa M., et al. Hepatitis E virus in donor plasma collected in Japan. Vox Sang. 2016; 111(3): 242–6. DOI: 10.1111/vox.12425.
43. Sakata H., Matsubayashi K., Iida J., et al. Trends in hepatitis E virus infection: Analyses of the long-term screening of blood donors in Hokkaido, Japan, 2005–2019. Transfusion. 2021; 61(12): 3390–401. DOI: 10.1111/trf.16700.
44. Cao L.C., Martin V., Linh L.T.K., et al. High Hepatitis E Virus (HEV) Seroprevalence and No Evidence of HEV Viraemia in Vietnamese Blood Donors. Viruses. 2023; 15(10): 2075. DOI: 10.3390/v15102075.
45. Intharasongkroh D., Thongmee T., Sa-Nguanmoo P., et al. Hepatitis E virus infection in Thai blood donors. Transfusion. 2019; 59: 1035–43. DOI: 10.1111/ trf.15041.
46. Mishra K.K., Patel K., Trivedi A., et al. Risk of hepatitis-E virus infections among blood donors in a regional blood transfusion centre in western India. Transfus Med. 2021; 31: 193–9. DOI: 10.1111/tme.12760.
47. Tripathy A,S., Puranik S., Sharma M.m et al. Hepatitis E virus seroprevalence among blood donors in Pune, India. J Med Virol. 2019; 91(5): 813–9. DOI: 10.1002/jmv.25370.
48. Al Dossary R.A., Alnafi e A.N., Aljaroodi S.A., et al. Prevalence of Hepatitis E Virus Infection Among Blood Donors in the Eastern Province of Saudi Arabia. J Multidiscip Healthc. 2021; 14: 2381–90. DOI: 10.2147/JMDH.S328029.
49. Parsa R., Adibzadeh S., Behzad Behbahani A., et al. Detection of Hepatitis E Virus Genotype 1 Among Blood Donors From Southwest of Iran. Hepat Mon. 2016; 16(6): e34202. DOI: 10.5812/hepatmon.34202.
50. Nasrallah G.K., Al Absi E.S., Ghandour R., et al. Seroprevalence of hepatitis E virus among blood donors in Qatar (2013–2016). Transfusion. 2017; 57(7): 1801–7. DOI: 10.1111/trf.14116.
51. Maponga T.G., Lopes T., Cable R., et al. Prevalence and risks of hepatitis E virus infection in blood donors from the Western Cape, South Africa. Vox Sang. 2020; 115: 695–702. DOI: 10.1111/vox.12966.
52. Meldal B.H., Sarkodie F., Owusu-Ofori S., Allain J.P. Hepatitis E virus infection in Ghanaian blood donors—The importance of immunoassay selection and confi rmation. Vox Sang. 2013; 104: 30–6. DOI: 10.1111/j.1423-0410.2012.01637.
53. Schreuder I., Limper M., Gerstenbluth I., et al. Hepatitis E virus infection among blood donors in the South Caribbean: Is screening warranted? Neth J Med. 2016; 74: 51–3.
54. Hewitt J., Harte D.S.M. Prevalence of hepatitis E virus antibodies and infection in New Zealand blood donors. N Z Med J. 2018; 131: 38–43.
55. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol. 2018; 68(6): 1256–71. DOI: 10.1016/j.jhep.2018.03.005.
56. Gallian P., Lhomme S., Piquet Y., et al. Hepatitis E virus infections in blood donors, France. Emerg Infect Dis. 2014; 20(11): 1914–7. DOI: 10.3201/eid2011.140516.
57. Lhomme S., Gallian P., Dimeglio C., et al. Viral load and clinical manifestations of hepatitis E virus genotype 3 infections. J Viral Hepat. 2019; 26: 1139–42. DOI: 10.1111/jvh.13128.
58. Hogema B.M., Molier M., Sjerps M., et al. Incidence and duration of hepatitis E virus infection in Dutch blood donors. Transfusion. 2016; 56(3): 722–8. DOI: 10.1111/trf.13402.
59. Harvala H., Hewitt P.E., Reynolds C., et al. Hepatitis E virus in blood donors in England, 2016 to 2017: From selective to universal screening. Euro Surveill. 2019; 24: 1800386. DOI: 10.2807/1560-7917.ES.2019.24.10.1800386.
60. German Advisory Committee Blood (Arbeitskreis Blut) Subgroup ‘Assessment of Pathogens Transmissible by Blood’. Transfus Med Hemother. 2015; 42(4): 247–65.
61. Paul-Ehrlich-Institut (PEI) Memorandum Stage 2: Arrangement of testing blood donors to prevent transmission of hepatitis E virus by blood components for transfusion and stem cell preparations for hematopoietic reconstitution. Funk, M. 5th February. 2019. Accessed 12th February 2019.
62. Bes M., Costafreda M.I., Riveiro-Barciela M., et al. Effect of Hepatitis E Virus RNA Universal Blood Donor Screening, Catalonia, Spain, 2017‒2020. Emerg Infect Dis. 2022; 28(1): 157–65. DOI: 10.3201/eid2801.211466.
63. Matsubayashi K., Nagaoka Y., Sakata H., et al. Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan. Transfusion. 2004; 44(6): 934–40. DOI: 10.1111/j.1537-2995.2004.03300.x.
64. Hauser L., Roque-Afonso A.M., Beylouné A., et al. Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. Blood. 2014; 123(5): 796–7. DOI: 10.1182/blood-2013-09-524348.
65. Satake M., Matsubayashi K., Hoshi Y., et al. Unique clinical courses of transfusion-transmitted hepatitis E in patients with immunosuppression. Transfusion. 2017; 57(2): 280–8. DOI: 10.1111/trf.13994.
66. Kamar N., Bendall R., Legrand-Abravanel F., et al. Hepatitis E. Lancet. 2012; 379: 2477–88.
67. Costafreda M.I., Sauleda S., Rico A., et al. Detection of Nonenveloped Hepatitis E Virus in Plasma of Infected Blood Donors. J Infect Dis. 2022; 226(10): 1753–60. DOI: 10.1093/infdis/jiab589.
68. Shahini E., Argentiero A., Andriano A., et al. Hepatitis E Virus: What More Do We Need to Know? Medicina (Kaunas). 2024; 60(6): 998. DOI: 10.3390/medicina60060998.
69. Mikhailov M.I., Karlsen A.A., Potemkin I.A., et al. Geographic and Temporal Variability of Hepatitis E Virus Circulation in the Russian Federation. Viruses. 2022; 15(1): 37. DOI: 10.3390/v15010037.
Review
For citations:
Potemkin I.A., Kyuregyan K.K., Mikhailov M.I. Hepatitis E in blood donors: prevalence, risks of posttransfusion infection and screening strategy. Russian journal of hematology and transfusiology. 2025;70(1):85-96. (In Russ.) https://doi.org/10.35754/0234-5730-2025-70-1-85-96
Views:
243
Email this article 
